These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 9609221)
1. Increased plasma levels of free tissue factor pathway inhibitor in patients with Graves' disease. Morishita E; Hashimoto T; Asakura H; Saito M; Yamazaki M; Aoshima K; Yoshida T; Kato H; Matsuda T Thromb Haemost; 1998 May; 79(5):919-23. PubMed ID: 9609221 [TBL] [Abstract][Full Text] [Related]
2. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormones. Morikawa Y; Morikawa A; Makino I J Clin Endocrinol Metab; 1993 Mar; 76(3):609-14. PubMed ID: 7680353 [TBL] [Abstract][Full Text] [Related]
3. Increased serum neopterin levels in patients with Graves' disease. Wagner R; Hayatghebi S; Rosenkranz M; Reinwein D Exp Clin Endocrinol; 1993; 101(4):249-54. PubMed ID: 8307114 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393 [TBL] [Abstract][Full Text] [Related]
5. Plasma leptin concentrations in patients with Graves' disease with or without ophthalmopathy. Ozata M; Uckaya G; Bolu E; Corapcioglu D; Bingol N; Ozdemir IC Med Sci Monit; 2001; 7(4):696-700. PubMed ID: 11433197 [TBL] [Abstract][Full Text] [Related]
6. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Bilgen D; Sönmez H; Ekmekçi H; Ulutin T; Oztürk Z; Kökoğlu E; Bayram C; Soner A; Domaniç N Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324 [TBL] [Abstract][Full Text] [Related]
7. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617 [TBL] [Abstract][Full Text] [Related]
8. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Erem C Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444 [TBL] [Abstract][Full Text] [Related]
9. Serum cytokines levels in Graves' disease. Al-Humaidi MA Saudi Med J; 2000 Jul; 21(7):639-44. PubMed ID: 11500727 [TBL] [Abstract][Full Text] [Related]
10. Hyperthyroidism is associated with higher plasma endothelin-1 concentrations. Chu CH; Lee JK; Keng HM; Chuang MJ; Lu CC; Wang MC; Sun CC; Wei MC; Lam HC Exp Biol Med (Maywood); 2006 Jun; 231(6):1040-3. PubMed ID: 16741045 [TBL] [Abstract][Full Text] [Related]
11. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease. Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404 [TBL] [Abstract][Full Text] [Related]
12. [Study of serum thrombomodulin(TM) levels in patients with hyper- or hypo- thyroidism]. Soma M; Maeda Y; Matsuura R; Sasaki I; Kasakura S; Saeki Y; Ikekubo K; Ishihara T; Kurahachi H; Sasaki S; Tagami T; Nakao K Rinsho Byori; 1997 Jan; 45(1):77-81. PubMed ID: 9022347 [TBL] [Abstract][Full Text] [Related]
13. Endothelin-1 levels in patients with disorders of the thyroid gland. Tilly N; Schneider JG; Leidig-Bruckner G; Sommer U; Kasperk C Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):80-4. PubMed ID: 12746758 [TBL] [Abstract][Full Text] [Related]
14. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Vos XG; Smit N; Endert E; Tijssen JG; Wiersinga WM Clin Endocrinol (Oxf); 2008 Aug; 69(2):311-7. PubMed ID: 18208575 [TBL] [Abstract][Full Text] [Related]
15. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease. Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540 [TBL] [Abstract][Full Text] [Related]
16. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. Morishita E; Asakura H; Saito M; Yamazaki M; Ontachi Y; Mizutani T; Kato M; Matsuda T; Nakao S Atherosclerosis; 2001 Jan; 154(1):203-12. PubMed ID: 11137101 [TBL] [Abstract][Full Text] [Related]
17. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Ozcan MA; Cömlekçi A; Demirkan F; Yüksel F; Sari I; Demir T; Ozsan GH; Orük G; Yeşil S; Undar B Thromb Res; 2003 Jun; 110(4):243-7. PubMed ID: 14512089 [TBL] [Abstract][Full Text] [Related]
18. Elevation of serum adiponectin levels in Basedow disease. Saito T; Kawano T; Saito T; Ikoma A; Namai K; Tamemoto H; Kawakami M; Ishikawa SE Metabolism; 2005 Nov; 54(11):1461-6. PubMed ID: 16253634 [TBL] [Abstract][Full Text] [Related]
19. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study. Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291 [TBL] [Abstract][Full Text] [Related]
20. Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases. Molnár I; Bokk A Cytokine; 2006 Aug; 35(3-4):109-14. PubMed ID: 17008110 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]